Clinical trial NCT04330313: Use of Different Electrophysical Agents in Cervical Region Flexibility Training of Healthy Individuals
Official title: Use of Different Electrophysical Agents in Cervical Region Flexibility Training of Healthy Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Flexibility
Stretch
Physical Therapy
Electrotherapy
Keywords: exercise
hotpack
laser therapy
traction
Lead sponsor: Pamukkale University
Sponsor class: OTHER
First posted: 2020-04-01
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: There are paralel groups, each has 15 participants. Different electrotherapy applications will be applied to each group.
Primary purpose: TREATMENT

Brief summary: 60 healthy participants with right / left upper trapezoidal shortness based on volunteering will be included in the study. Participants were randomly divided into 4 groups; Traction and stretching exercises to group 1 (n = 15), laser therapy and stretching exercise to group 2 (n = 15), hot pack and stretching exercises to group 3 (n = 15), and group 4 (control group) only stretching exercises will be applied.

Detailed description: Healthy individuals without any cervical region pathology will be included in the study. Exclusion criterias are pregnancy or cancer, hypertension that cannot be controlled, having neurological symptoms, previous spinal surgery.

Demographic information of the participants will be recorded; cervical joint range of motion (CROM device), muscle shortness (acromion-earlobe and occiput-wall distance measurement), deep cervical flexor muscle strength (Stabilizer Pressure Biofeedback), cervical performance level (Cervical Performance Tests), muscle spasm (Palpable Muscle Spasm Scoring) will be evaluated. Cervical joint range of motion and muscle shortening will be repeated before and after each session, but other parameters will only be repeated at the beginning and the end.

Eligibility criteria: Inclusion Criteria:

-Healthy individuals without any cervical region pathology

Exclusion Criteria:

* Pregnancy and cancer
* Uncontrolled hypertension
* Presence of neurological symptoms
* Spinal surgery history

Primary outcomes:
measure: Cervical range of motion (ROM)
timeFrame: Baseline to 6 weeks after
measure: Cervical flexibility
timeFrame: Baseline to 6 weeks after
Secondary outcomes:
measure: Cervikal Muscle spasm
timeFrame: Baseline to 6 weeks after
Other outcomes:
measure: Cervical Performance Level
timeFrame: Baseline to 6 weeks after
measure: Muscle Strength of Deep Cervical Flexor Muscles
timeFrame: Baseline to 6 weeks after
Locations:
city: Denizli
country: Turkey
facility: Pamukkale University
Study officials:
affiliation: Pamukkale University
name: Şule ŞİMŞEK, PhD
role: STUDY_CHAIR
affiliation: Pamukkale University
name: Ummuhan BAŞ ASLAN, Prof. Dr.
role: STUDY_CHAIR
affiliation: Denizli Devlet Hastanesi
name: Merve BERGİN KORKMAZ, Dr.
role: STUDY_CHAIR
References:
citation: Audette I, Dumas JP, Cote JN, De Serres SJ. Validity and between-day reliability of the cervical range of motion (CROM) device. J Orthop Sports Phys Ther. 2010 May;40(5):318-23. doi: 10.2519/jospt.2010.3180.
citation: Hudswell, S., von Mengersen, M., Lucas, N. The cranio-cervical flexion test using pressure biofeedback: A useful measure of cervical dysfunction in the clinical setting? International Journal of Osteopathic Medicine. 2005; 8(3): 98-105.
citation: Shahidi B, Johnson CL, Curran-Everett D, Maluf KS. Reliability and group differences in quantitative cervicothoracic measures among individuals with and without chronic neck pain. BMC Musculoskelet Disord. 2012 Oct 31;13:215. doi: 10.1186/1471-2474-13-215.
citation: Zhang LL, Zhou GQ, Qi ZY, He XJ, Li JX, Tang LL, Mao YP, Lin AH, Ma J, Sun Y. Patient- and treatment-related risk factors associated with neck muscle spasm in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy. BMC Cancer. 2017 Nov 23;17(1):788. doi: 10.1186/s12885-017-3780-9.